PMN · ProMIS Neurosciences Inc.
AI read · Good for PMN
The AI's read
The cash is expected to last beyond the planned trial readout, giving ProMIS time to report full results. Earlier checks found encouraging safety and biomarker changes, but have not shown whether PMN310 slows Alzheimer's disease. PMN310 is designed to target toxic amyloid clumps, and the company has hired an experienced Alzheimer's commercial leader. The full test of whether the treatment helps patients is still ahead.